- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00392496
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. Determine the response rate in patients with relapsed or refractory, diffuse or mediastinal, large B-cell lymphoma treated with sunitinib malate.
II. Determine the toxicity of this drug in these patients. III. Determine the effects of this drug on peripheral blood biomarkers, circulating endothelial cells, and their precursors in these patients.
OUTLINE: This is a non-randomized, open-label, multicenter study.
Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 3N6
- National Cancer Institute of Canada Clinical Trials Group
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Criteria:
- Histologically confirmed diffuse or mediastinal large B-cell lymphoma*, meeting the following criteria: Advanced or metastatic disease, Incurable by standard therapies, Relapsed or refractory disease [Note: *Patients with diffuse large B-cell lymphoma whose disease has transformed from an earlier diagnosis of low grade lymphoma (i.e., an indolent histology) are eligible]
- Bidimensionally measurable disease** by CT scan, MRI, or physical exam, with >= 1 disease site meeting 1 of the following criteria: Lymph nodes >= 1.5 cm x 1.5 cm by spiral CT scan, Non-nodal regions >= 1 cm x 1 cm by MRI, CT scan, or physical exam [Note: **Bone lesions are not considered bidimensionally measurable disease]
- Received 1-2 prior chemotherapy regimens that included doxorubicin hydrochloride; Prior stem cell transplantation and high-dose chemotherapy is considered one regimen; One prior non-chemotherapy regimen in the form of radiation allowed; Measurable disease must be outside the previously irradiated area;
- No sole site of disease in a previously irradiated area unless progressive disease or new lesions are documented; Low-dose palliative radiotherapy may be allowed
- No known brain metastases
- Life expectancy >= 12 weeks
- ECOG performance status 0-1
- Absolute granulocyte count >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- AST and ALT =< 2.5 times upper limit of normal (ULN)
- Bilirubin normal
- Calcium =< 3 mmol/L
- Creatinine =< 1.25 times ULN OR creatinine clearance >= 60 mL/min
- LVEF normal by MUGA
- None of the following in the past 12 months: cardiac arrhythmia, cerebrovascular accident (CVA), coronary/peripheral artery bypass graft or stenting, myocardial infarction, stable or unstable angina, symptomatic congestive heart failure, transient ischemic attack, pulmonary embolism
- No uncontrolled hypertension (systolic blood pressure >= 140 mm Hg or diastolic blood pressure >= 90 mm Hg)
- No New York Heart Association (NYHA) class III or IV heart disease
- No QTc prolongation (QTc interval >= 500 msec) or other significant ECG abnormalities
- No other prior malignancies except nonmelanoma skin cancer, in situ cervical cancer, or other solid tumors curatively treated with no evidence of disease for >= 5 years
- No history of allergic reaction to compounds of similar chemical or biological composition to sunitinib malate
- No other serious illness or medical condition that would preclude study participation, including, but not limited to, the following:
active, uncontrolled infection, serious or nonhealing wound, ulcer, or bone fracture, history of significant neurologic or psychiatric disorder that would impair the ability to obtain consent or limit compliance
- Other medical condition that might be aggravated by treatment
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- No bowel obstruction
- No condition that would impair the ability to swallow and retain sunitinib malate tablets, including any of the following:
Gastrointestinal tract disease resulting in inability to take oral medication or a requirement for IV alimentation, Prior surgical procedures affecting absorption, Active peptic ulcer disease
- No pre-existing hypothyroidism unless euthyroid on medication
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- At least 28 days since prior chemotherapy
- At least 28 days since prior radiotherapy and recovered; radiotherapy must have involved < 30% of functioning bone marrow
- At least 28 days since prior major surgery and recovered
- At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following: rifampin, phenytoin, rifabutin, hypericum perforatum (St. John's wort), carbamazepine, efavirenz, phenobarbital, tipranavir,
- At least 7 days since prior and concurrent CYP3A4 inhibitors, including any of the following: azole antifungals (e.g., ketoconazole, itraconazole), verapamil, clarithromycin, HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, nelfinavir), erythromycin, delavirdine, diltiazem,
- No prior therapy with other antiangiogenic agents or multitargeted tyrosine kinase inhibitors, including any of the following:
bevacizumab, sorafenib tosylate, pazopanib, thalidomide, AZD2171 vandetanib, AMG 706, vatalanib, VEGF Trap
- No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin); Concurrent dosing of =< 2 mg of warfarin daily for prophylaxis of thrombosis is allowed; Concurrent low molecular weight heparin is allowed provided INR is =< 1.5
- No other concurrent anticancer treatments, including investigational agents
- No concurrent agents with proarrhythmic potential, including any of the following: terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, flecainide
- No concurrent combination antiretroviral therapy for HIV-positive patients
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Arm I
This is a non-randomized, open-label, multicenter study.
Patients receive sunitinib malate orally once daily on days 1-28.
Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
|
Dato oralmente
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Objective Tumor Response
Lasso di tempo: Up to 3 years
|
It is defined as per the Report of the International workshop to standardize response criteria for non-Hodgkin's lymphoma and reviewed independently
|
Up to 3 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Rena Buckstein, Canadian Cancer Trials Group
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Linfoma, cellule B
- Linfoma
- Linfoma, a grandi cellule B, diffuso
- Linfoma non Hodgkin
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Inibitori della chinasi proteica
- Sunitinib
Altri numeri di identificazione dello studio
- NCI-2009-00692 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- CDR0000652059
- NCIC-182 (Altro identificatore: CTEP)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su sunitinib malato
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletatoCancro ovarico epiteliale refrattario al platino | Cancro primario del peritoneo | Cancro della tuba di FalloppioGermania
-
Cogent Biosciences, Inc.ReclutamentoCancro metastatico | Tumori stromali gastrointestinali avanzatiStati Uniti, Corea, Repubblica di, Spagna, Regno Unito, Australia, Francia, Italia, Olanda, Taiwan, Germania, Danimarca, Hong Kong, Canada, Svezia, Norvegia, Messico, Cechia, Argentina, Ungheria, Brasile, Chile, Polonia
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletatoCancro ai reniStati Uniti
-
PfizerCompletatoNeoplasie mammarieStati Uniti
-
Asan Medical CenterCompletatoCarcinoma a cellule renali metastaticoCorea, Repubblica di
-
National Cancer Institute (NCI)CompletatoCancro del collo squamoso metastatico ricorrente con primario occulto | Carcinoma a cellule squamose ricorrente dell'ipofaringe | Carcinoma a cellule squamose ricorrente della laringe | Carcinoma a cellule squamose ricorrente del labbro e della cavità orale | Carcinoma a cellule squamose ricorrente... e altre condizioniStati Uniti
-
PfizerCompletatoTumori stromali gastrointestinaliCorea, Repubblica di
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompletatoMelanoma metastaticoStati Uniti
-
National Cancer Institute (NCI)CompletatoSindromi mielodisplastiche | Leucemia Mielomonocitica Cronica | Sindromi mielodisplastiche secondarie | Sindromi Mielodisplastiche de NovoCanada, Stati Uniti
-
National Cancer Institute (NCI)CompletatoMieloma multiplo stadio I | Mieloma multiplo stadio II | Mieloma multiplo stadio III | Mieloma multiplo refrattarioStati Uniti